Skip to main content

Compare Stocks

Date Range: 

 Vor BiopharmaNurix TherapeuticsPureTech HealthSilverback Therapeutics4D Molecular Therapeutics
SymbolNYSE:VORNASDAQ:NRIXLON:PRTCNASDAQ:SBTXNASDAQ:FDMT
Price Information
Current Price$19.51$25.89GBX 360.50$26.40$26.33
52 Week RangeBuyBuyBuyBuyBuy
MarketRank™
Overall Score1.52.01.51.71.3
Analysis Score4.33.53.53.53.3
Community Score3.24.13.84.43.3
Dividend Score0.00.00.00.00.0
Ownership Score0.01.70.00.00.0
Earnings & Valuation Score0.00.60.00.60.0
Analyst Ratings
Consensus RecommendationBuyBuyBuyBuyBuy
Consensus Price Target$48.20$46.00GBX 496.25$50.25$45.50
% Upside from Price Target147.05% upside77.67% upside37.66% upside90.34% upside72.81% upside
Trade Information
Market Cap$731.50 million$1.12 billion£1.03 billion$862.45 million$705.26 million
BetaN/AN/AN/AN/AN/A
Average Volume232,808459,851236,715214,772150,651
Sales & Book Value
Annual RevenueN/AN/A£11.77 millionN/AN/A
Price / SalesN/AN/A87.58N/AN/A
CashflowN/AN/AGBX 138.04 per shareN/AN/A
Price / CashN/AN/A2.61N/AN/A
Book ValueN/AN/AGBX 234.30 per shareN/AN/A
Price / BookN/AN/A0.02N/AN/A
Profitability
Net IncomeN/AN/AN/AN/AN/A
EPSN/AN/AGBX 1.40N/AN/A
Trailing P/E Ratio0.000.00257.500.000.00
Forward P/E RatioN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net MarginsN/AN/AN/AN/AN/A
Return on Equity (ROE)N/AN/AN/AN/AN/A
Return on Assets (ROA)N/AN/AN/AN/AN/A
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/AN/A11.72%N/AN/A
Current RatioN/AN/A2.29%N/AN/A
Quick RatioN/AN/A2.25%N/AN/A
Ownership Information
Institutional Ownership PercentageN/A81.99%N/AN/AN/A
Insider Ownership PercentageN/AN/AN/AN/AN/A
Miscellaneous
Employees881353005483
Shares Outstanding37.13 million44.35 million285.90 million34.90 million26.69 million
Next Earnings Date8/5/2021 (Estimated)N/AN/A8/12/2021 (Estimated)8/12/2021 (Estimated)
OptionableNot OptionableNot OptionableNot OptionableNot OptionableNot Optionable
SourceHeadline
4D Molecular Therapeutics (NASDAQ:FDMT) Issues  Earnings Results4D Molecular Therapeutics (NASDAQ:FDMT) Issues Earnings Results
americanbankingnews.com - May 14 at 11:50 AM
4D Molecular Therapeutics Reports Financial Results for the First Quarter of 2021 and Provides Operational Highlights4D Molecular Therapeutics Reports Financial Results for the First Quarter of 2021 and Provides Operational Highlights
finance.yahoo.com - May 14 at 12:04 AM
4D Molecular Therapeutics Presents Non-Human Primate Preclinical Data at ASGCT on the 4D-150 ...4D Molecular Therapeutics Presents Non-Human Primate Preclinical Data at ASGCT on the 4D-150 ...
apnews.com - May 13 at 7:22 AM
4D Molecular Therapeutics Presents Non-Human Primate Preclinical Data at ASGCT on the 4D-150 Product Candidate for wet AMD and DME4D Molecular Therapeutics Presents Non-Human Primate Preclinical Data at ASGCT on the 4D-150 Product Candidate for wet AMD and DME
finance.yahoo.com - May 12 at 9:11 PM
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Insiders Increased Their Holdings4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Insiders Increased Their Holdings
finance.yahoo.com - May 10 at 4:00 PM
4D Molecular Therapeutics Announces Collaboration on Leading Machine Learning Technology and Expertise from U.C. Berkeley to Expand Therapeutic Vector Evolution Platform4D Molecular Therapeutics Announces Collaboration on Leading Machine Learning Technology and Expertise from U.C. Berkeley to Expand Therapeutic Vector Evolution Platform
finance.yahoo.com - May 4 at 8:20 PM
4D Molecular Therapeutics to Participate in BofA Securities 2021 Virtual Health Care Conference4D Molecular Therapeutics to Participate in BofA Securities 2021 Virtual Health Care Conference
finance.yahoo.com - April 30 at 9:29 AM
4D Molecular Therapeutics Announces Preclinical Data Presentations at ASGCT and ATS Annual Meetings on Three Wholly-Owned Product Candidates from Non-Human Primate Studies4D Molecular Therapeutics Announces Preclinical Data Presentations at ASGCT and ATS Annual Meetings on Three Wholly-Owned Product Candidates from Non-Human Primate Studies
finance.yahoo.com - April 27 at 5:52 PM
Is FDMT Stock A Buy or Sell?Is FDMT Stock A Buy or Sell?
finance.yahoo.com - April 26 at 3:08 PM
What Kind Of Shareholders Hold The Majority In 4D Molecular Therapeutics, Inc.s (NASDAQ:FDMT) Shares?What Kind Of Shareholders Hold The Majority In 4D Molecular Therapeutics, Inc.'s (NASDAQ:FDMT) Shares?
nasdaq.com - April 17 at 5:27 PM
4D Molecular Therapeutics Reports Financial Results for the Year Ended December 31, 2020 and Provides Operational Highlights4D Molecular Therapeutics Reports Financial Results for the Year Ended December 31, 2020 and Provides Operational Highlights
finance.yahoo.com - March 25 at 6:10 PM
We Think 4D Molecular Therapeutics (NASDAQ:FDMT) Can Afford To Drive Business GrowthWe Think 4D Molecular Therapeutics (NASDAQ:FDMT) Can Afford To Drive Business Growth
finance.yahoo.com - March 11 at 8:12 AM
Genetic Modification Therapies Market Share, Development by Companies Outlook, Growth Prospects and Key Opportunities by 2030Genetic Modification Therapies Market Share, Development by Companies Outlook, Growth Prospects and Key Opportunities by 2030
marketwatch.com - March 11 at 1:08 AM
4D Molecular Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of 4D-310 ...4D Molecular Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of 4D-310 ...
apnews.com - March 9 at 9:09 AM
4D Molecular Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of 4D-310 for the Treatment of Fabry Disease4D Molecular Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of 4D-310 for the Treatment of Fabry Disease
finance.yahoo.com - March 9 at 9:09 AM
4D Molecular Therapeutics, Inc. Common Stock (FDMT)4D Molecular Therapeutics, Inc. Common Stock (FDMT)
nasdaq.com - January 31 at 12:42 AM
4D Molecular Therapeutics Inc4D Molecular Therapeutics Inc
money.usnews.com - December 16 at 11:40 PM
BioAtla Is the Latest Biotech IPO to PopBioAtla Is the Latest Biotech IPO to Pop
finance.yahoo.com - December 16 at 6:39 PM
4D Molecular Therapeutics Announces Closing of Initial Public Offering and Full Exercise of ...4D Molecular Therapeutics Announces Closing of Initial Public Offering and Full Exercise of ...
apnews.com - December 16 at 8:39 AM
DateCompanyBrokerageAction
5/7/2021Vor BiopharmaB. RileyReiterated Rating
3/9/2021Vor BiopharmaBarclaysInitiated Coverage
3/8/2021Vor BiopharmaThe Goldman Sachs GroupInitiated Coverage
3/8/2021Vor BiopharmaStifel NicolausInitiated Coverage
3/8/2021Vor BiopharmaEvercore ISIInitiated Coverage
5/6/2021Nurix TherapeuticsRoyal Bank of CanadaInitiated Coverage
4/20/2021Nurix TherapeuticsBerenberg BankInitiated Coverage
2/17/2021Nurix TherapeuticsNeedham & Company LLCReiterated Rating
2/17/2021Nurix TherapeuticsPiper SandlerBoost Price Target
1/29/2021Nurix TherapeuticsJPMorgan Chase & Co.Boost Price Target
11/18/2020Nurix TherapeuticsRobert W. BairdInitiated Coverage
4/15/2021PureTech HealthLiberum CapitalReiterated Rating
1/19/2021PureTech HealthJefferies Financial GroupReiterated Rating
7/8/2020PureTech HealthPeel HuntReiterated Rating
6/2/2020PureTech HealthPeel HuntReiterated Rating
4/13/2021Silverback TherapeuticsSVB LeerinkBoost Price Target
12/29/2020Silverback TherapeuticsHC WainwrightInitiated Coverage
1/5/20214D Molecular TherapeuticsBank of AmericaInitiated Coverage
(Data available from 5/14/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.